Amendments to the Specification:

Please replace paragraph [0001] with the following amended paragraph:

This application is a continuation of International Patent Application No. PCT/US/17402, filed May 31, 2002, which claims priority to U.S. Provisional Application Nos. 60/295,449, filed June 1, 2001, expired, and 60/295,907, filed June 4, 2001, expired.

Please replace paragraph [0030] with the following amended paragraph:

FIG. 1B is a set of graphs showing binding of monoclonal antibodies ABE3, AKG7 and ACA12 to peptides 43 to 50 at various concentrations of antibody (peptide 43 corresponds to amino acids 210-227 of SEQ ID NO:7; peptide 44 corresponds to amino acids 219-236 of SEQ ID NO:7; peptide 45 corresponds to amino acids 228-245 of SEQ ID NO:7; peptide 46 corresponds to amino acids 237-254 of SEQ ID NO:7; peptide 47 corresponds to amino acids 246-263 of SEQ ID NO:7; peptide 48 corresponds to amino acids 255-272 of SEQ ID NO:7; peptide 49 corresponds to amino acids 264-281 of SEQ ID NO:7; and peptide 50 corresponds to amino acids 273-290 of SEQ ID NO:7).

Please replace paragraph [0053] with the following amended paragraph:

A hybridoma that produces monoclonal antibody subclone ABE3.16 was deposited with the American Type Culture Collection at 10801 University Boulevard, Manassas, VA 20110-2209 ~~12301 Parklawn Drive, Rockville, MD., 20852~~ (U.S.A.) on May 2, 2001, and has been assigned Accession Number PTA-3350. ABE3.16 is a subclone of ABE3.

Please replace paragraph [0084] with the following amended paragraph:

Monoclonal antibody ABE3 bound to peptide #49 but did not show substantial binding to either peptide #48 or #50. These observations suggested that the binding epitope of ABE3 is around DGLWNNNQTQL (amino acids 3-13 of SEQ ID NO:1). This sequence includes a potential glycosylation site at the last asparagine residue. However, since ABE3 bound to

synthetic peptides as well as to various glycosylated forms of KIM-1, it was concluded that binding of ABE3 is primarily to a peptide moiety.